The objective of N²M² is the improvement of overall survival of patients with glioblastoma
with an unmethylated MGMT promoter based on molecular characterization and use of targeted
compounds in a modern trial design. The progression-free survival rate at six months (PFS-6)
will be used to make decisions.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University Hospital Heidelberg
Collaborators:
German Cancer Aid German Cancer Research Center National Center for Tumor Diseases, Heidelberg